Gastroesophageal Reflux Clinical Trial
Official title:
Esophageal Bolus Transit in GERD Newborns: a Multichannel Intraluminal Impedance Study
Esophageal dysmotility due to immaturity could promote impaired bolus transit during
esophageal swallow events,thus influencing gastroesophageal reflux (GER) clearance.
Aim of this study was to describe esophageal bolus transit characteristics during swallow and
to evaluate the relationship between esophageal swallow (ES) and GER in newborns with
gastroesophageal reflux disease symptoms using multichannel intraluminal impedance.
The simultaneous analysis of swallow and GER events in newborns undergone MII/pH monitoring
could provide useful information to better understand the physiopathology of gastroesophageal
reflux disease (GERD) and could help clinicians to identify newborns with prolonged
esophageal clearance time, making the recommendations for further tests and the therapeutic
approach more accurate
The aim of this study was to evaluate esophageal swallow (ES) frequency and characteristics
in term and preterm newborns with GERD symptoms using MII and to investigate the possible
relationship between ES and GER events.
MATERIAL AND METHODS
The MII tracings from the beginning of the second feeding up to 3 hours after the end of the
meal were visually analyzed by two independent investigators using Bioview Analysis software
(Sandhill Scientific Inc., Highlands Ranch, Colorado, USA) to identify and characterize ES
and GER events.
ES events An ES event was identified as a rapid increase in impedance which precedes a drop
in impedance to 50% of baseline beginning in the proximal channel and preceding in an
anterograde direction to the most distal channel, followed by the recovery of baseline values
at each channel.13 The ES events detected by MII/pH were grouped into mealtime events (the
first nine consecutive ES events with no artifacts after the beginning of the meal) and
postprandial period events (all the ES events detected in the 3 hours following the end of
the meal).
ES event frequency (ES events/hour) was measured, along with the following ES event
characteristics:
bolus presence time (BPT): time between bolus entrance and exit recorded in the distal
channel, measured in seconds; bolus head advancing time (BHAT): time between the bolus
entrance recorded in the proximal channel and the bolus entrance recorded in the distal
channel, measured in seconds; bolus head advancing time corrected (BHATc): BHAT corrected for
esophageal length, expressed in seconds/cm. BHATc was calculated using the formula BHATc =
BHAT / esophageal length where esophageal length is the distance between proximal and distal
impedance channels, measured in cm.
GER events
A GER event was defined as a retrograde drop in impedance to 50% of baseline, beginning in
the most distal channel and proceding to one or more proximal channels, of at least 5
seconds, followed by an impedance recovery of baseline values.GER event frequency was
measured (GER events/hour), along with the following event characteristics:
bolus reflux extent (BRE):the proximal extent reached by the refluxate, shown by the number
of channels sequentially involved in the impedance drop,measured in number of channels; bolus
clearance time (BCT):time from onset, at the 50% drop in impedance signal from baseline, to
the end of the event, at the 50% recovery point from nadir to baseline, recorded in the
distal impedance channel, measured in second.
Statistical Analysis The distribution of all the continuous variables was assessed by the
Shapiro-Wilk test. The differences in MII variables between different groups of infants were
evaluated with the Mann-Whitney test; the Wilcoxon test was used to compare paired data.
Group correlations were analyzedwith the Spearman correlation test. Statistical significance
was set at p<0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |